An ongoing phase III head-to-head study compares the PD-L1 inhibitor serplulimab to the PD-L1 inhibitor atezolizumab plus chemotherapy as first-line treatment for ES-SCLC (NCT05468489). The gene discussed is CD274; the disease is small cell lung carcinoma.